Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1

References

• Attard G, Parker C, Eeles R, Schröder F, Tomlins S, Tannock I, Drake C, de Bono J. 2016. Prostate cancer. Lancet. 387(10013):70–82. doi:10.1016/S0140-6736(14)61947-4.
   PubMed Web of Science ®Google Scholar
• Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532–2542. doi:10.1001/jama.2017.7248. PMID:28655021.
   PubMed Web of Science ®Google Scholar
• Wade CA, Kyprianou N. Profiling prostate cancer therapeutic resistance. Int J Mol Sci. 2018;19(3):E904. doi:10.3390/ijms19030904. PMID:29562686.
   PubMed Web of Science ®Google Scholar
• Wei Y, Pu X, Zhao L. Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review). Oncol Rep. 2017;37(6):3159–3166. doi:10.3892/or.2017.5593. PMID:28440434.
   PubMed Web of Science ®Google Scholar
• Klinge CM. Non-coding RNAs: long non-coding RNAs and microRNAs in endocrine-related cancers. Endocr Relat Cancer. 2018;25(4):R259–R82. doi:10.1530/ERC-17-0548. PMID:29440232.
   PubMed Web of Science ®Google Scholar
• Xu T, Lin CM, Cheng SQ, Min J, Li L, Meng XM, Huang C, Zhang L, Deng ZY, Li J. Pathological bases and clinical impact of long noncoding RNAs in prostate cancer: a new budding star. Mol Cancer. 2018;17(1):103. doi:10.1186/s12943-018-0852-7. PMID:30037351.
   PubMedGoogle Scholar
• Smolle MA, Bauernhofer T, Pummer K, Calin GA, Pichler M. Current insights into long non-coding RNAs (LncRNAs) in prostate cancer. Int J Mol Sci. 2017;18(2):E473. doi:10.3390/ijms18020473. PMID:28241429.
   PubMed Web of Science ®Google Scholar
• Wang N, Yu Y, Xu B, Zhang M, Li Q, Miao L. Pivotal prognostic and diagnostic role of the long noncoding RNA colon cancerassociated transcript 1 expression in human cancer (Review). Mol Med Rep. 2019;19(2):771–782. doi:10.3892/mmr.2018.9721. PMID:30535444.
   PubMed Web of Science ®Google Scholar
• Fang H, Liu HM, Wu WH, Liu H, Pan Y, Li WJ. Upregulation of long noncoding RNA CCAT1-L promotes epithelial-mesenchymal transition in gastric adenocarcinoma. Onco Targets Ther. 2018;11:5647–5655. doi:10.2147/OTT.S170553. PMID:30254457.
   PubMed Web of Science ®Google Scholar
• Lai XJ, Cheng HF. LncRNA colon cancer-associated transcript 1 (CCAT1) promotes proliferation and metastasis of ovarian cancer via miR-1290. Eur Rev Med Pharmacol Sci. 2018;22(2):322–328. doi:10.26355/eurrev_201801_14175. PMID:29424889.
   PubMed Web of Science ®Google Scholar
• Dong Y, Yuan H, Jin G. Identification of long non-coding RNA CCAT1 as an oncogene in nasopharyngeal carcinoma. Oncol Lett. 2018;16(2):2750–2756. doi:10.3892/ol.2018.8969. PMID:30013670.
   PubMed Web of Science ®Google Scholar
• Lin H, Cheng W, Yan H, Zhang X. Overexpression of the long noncoding RNA CCAT1 promotes metastasis via epithelial-to-mesenchymal transition in lung adenocarcinoma. Oncol Lett. 2018;16(2):1809–1814. doi:10.3892/ol.2018.8813. PMID:30008869.
   PubMed Web of Science ®Google Scholar
• Chen H, He Y, Hou YS, Chen DQ, He SL, Cao YF, Wu XM. Long non-coding RNA CCAT1 promotes the migration and invasion of prostate cancer PC-3 cells. Eur Rev Med Pharmacol Sci. 2018;22(10):2991–2996. doi:10.26355/eurrev_201805_15055. PMID:29863242.
   PubMed Web of Science ®Google Scholar
• Li F, Mahato RI. MicroRNAs and drug resistance in prostate cancers. Mol Pharm. 2014;11(8):2539–2552. doi:10.1021/mp500099g. PMID:24742219.
   PubMedGoogle Scholar
• Olbromski M, Rzechonek A, Grzegrzolka J, Glatzel-Plucinska N, Chachaj A, Werynska B, Podhorska-Okolow M, Dziegiel P. Influence of miR-7a and miR-24-3p on the SOX18 transcript in lung adenocarcinoma. Oncol Rep. 2018;39(1):201–208. doi:10.3892/or.2017.6077. PMID:29115529.
   PubMed Web of Science ®Google Scholar
• Fan JC, Zeng F, Le YG, Xin L. LncRNA CASC2 inhibited the viability and induced the apoptosis of hepatocellular carcinoma cells through regulating miR-24-3p. J Cell Biochem. 2018;119(8):6391–6397. doi:10.1002/jcb.26479. PMID:29091305.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu Y, Du L, Li J, Qu A, Zhang X, Wang L, Wang C. Down-regulation of miR-24-3p in colorectal cancer is associated with malignant behavior. Med Oncol. 2015;32(1):362. doi:10.1007/s12032-014-0362-4. PMID:25502080.
   PubMed Web of Science ®Google Scholar
• Fredsoe J, Rasmussen AKI, Thomsen AR, Mouritzen P, Hoyer S, Borre M, Orntoft TF, Sorensen KD. Diagnostic and prognostic MicroRNA biomarkers for prostate cancer in cell-free urine. Eur Urol Focus. 2018;4(6):825–833. doi:10.1016/j.euf.2017.02.018. PMID:28753866.
   PubMedGoogle Scholar
• Hashimoto Y, Kim DJ, Adams JC. The roles of fascins in health and disease. J Pathol. 2011;224(3):289–300. doi:10.1002/path.2894. PMID:21618240.
   PubMed Web of Science ®Google Scholar
• Xu W, Chang J, Du X, Hou J. Long non-coding RNA PCAT-1 contributes to tumorigenesis by regulating FSCN1 via miR-145-5p in prostate cancer. Biomed Pharmacother. 2017;95:1112–1118. doi:10.1016/j.biopha.2017.09.019. PMID:28922730.
   PubMed Web of Science ®Google Scholar
• Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T, et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 2011;38(4):1093–1101. doi:10.3892/ijo.2011.919. PMID:21258769.
   PubMed Web of Science ®Google Scholar
• Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET, Namiki M. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate. 2007;67(9):955–967. doi:10.1002/pros.20581. PMID:17440963.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262. PMID:11846609.
   PubMed Web of Science ®Google Scholar
• Zhang W, Meng Y, Liu N, Wen XF, Yang T. Insights into chemoresistance of prostate cancer. Int J Biol Sci. 2015;11(10):1160–1170. doi:10.7150/ijbs.11439. PMID:26327810.
   PubMed Web of Science ®Google Scholar
• Ma G, Tang M, Wu Y, Xu X, Pan F, Xu R. LncRNAs and miRNAs: potential biomarkers and therapeutic targets for prostate cancer. Am J Transl Res. 2016;8(12):5141–5150. PMID:28077991.
   PubMed Web of Science ®Google Scholar
• Guo X, Hua Y. CCAT1: an oncogenic long noncoding RNA in human cancers. J Cancer Res Clin Oncol. 2017;143(4):555–562. doi:10.1007/s00432-016-2268-3. PMID:27638771.
   PubMed Web of Science ®Google Scholar
• Karnak D, Xu L. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets. 2010;11(6):699–707. PMID: 20298153.
   PubMed Web of Science ®Google Scholar
• Hu B, Zhang H, Wang Z, Zhang F, Wei H, Li L. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Cancer Biol Ther. 2017;18(12):974–983. doi:10.1080/15384047.2017.1385679. PMID:29020498.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang K, Song H, Wang R, Chu X, Chen L. Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells. Oncotarget. 2016;7(38):62474–62489. doi:10.18632/oncotarget.11518. PMID:27566568.
   PubMedGoogle Scholar
• Wang Q, Zhang W, Hao S. LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis. Cell Cycle. 2017;16(8):795–801. doi:10.1080/15384101.2017.1301334. PMID:28358263.
   PubMed Web of Science ®Google Scholar
• Sun X, Xiao D, Xu T, Yuan Y. miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5. Future Oncol. 2016;12(23):2701–2712. doi:10.2217/fon-2016-0179. PMID:27513190.
   PubMed Web of Science ®Google Scholar
• Pan B, Chen Y, Song H, Xu Y, Wang R, Chen L. Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A. Oncotarget. 2015;6(1):317–331. doi:10.18632/oncotarget.2787. PMID:25426560.
   PubMedGoogle Scholar
• Li YQ, Lu JH, Bao XM, Wang XF, Wu JH, Hong WQ. MiR-24 functions as a tumor suppressor in nasopharyngeal carcinoma through targeting FSCN1. J Exp Clin Cancer Res. 2015;34:130. doi:10.1186/s13046-015-0242-6. PMID:26503504.
   PubMed Web of Science ®Google Scholar
• Tan VY, Lewis SJ, Adams JC, Martin RM. Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med. 2013;11:52. doi:10.1186/1741-7015-11-52. PMID:23442983.
   PubMed Web of Science ®Google Scholar
• Maeda O, Ando T, Ohmiya N, Ishiguro K, Watanabe O, Miyahara R, Hibi Y, Nagai T, Yamada K, Goto H. Alteration of gene expression and DNA methylation in drug-resistant gastric cancer. Oncol Rep. 2014;31(4):1883–1890. doi:10.3892/or.2014.3014. PMID:24504010.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lu Y, Zhang C, Huang D, Wu W, Zhang Y, Shen J, Cai Y, Chen W, Yao W. FSCN1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition. Int J Oncol. 2018;52(5):1455–1464. doi:10.3892/ijo.2018.4327. PMID:29568938.
   PubMed Web of Science ®Google Scholar